Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.

Draht MXG, Goudkade D, Koch A, Grabsch HI, Weijenberg MP, van Engeland M, Melotte V, Smits KM.

Clin Epigenetics. 2018 Mar 14;10:35. doi: 10.1186/s13148-018-0461-8. eCollection 2018. Review.

2.

Signet ring cell carcinoma in the stomach: Histopathological definitions and response to therapy assessment - The urgent need for an international consensus.

Grabsch HI; European Chapter of the International Gastric Cancer Association.

Eur J Cancer. 2018 Mar;92 Suppl 2:S3-S4. doi: 10.1016/j.ejca.2018.01.096. No abstract available.

PMID:
29553388
3.

Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.

Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI.

Eur J Cancer. 2018 May;94:104-114. doi: 10.1016/j.ejca.2018.02.014. Epub 2018 Mar 20.

4.

Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.

Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI.

Histopathology. 2018 Jun;72(7):1180-1188. doi: 10.1111/his.13491. Epub 2018 Mar 25.

5.

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE.

Lancet Oncol. 2017 Sep;18(9):1249-1260. doi: 10.1016/S1470-2045(17)30447-3. Epub 2017 Aug 4.

6.

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.

Mukherjee S, Hurt CN, Gwynne S, Sebag-Montefiore D, Radhakrishna G, Gollins S, Hawkins M, Grabsch HI, Jones G, Falk S, Sharma R, Bateman A, Roy R, Ray R, Canham J, Griffiths G, Maughan T, Crosby T.

Eur J Cancer. 2017 Mar;74:38-46. doi: 10.1016/j.ejca.2016.11.031. Epub 2017 Feb 8.

7.

MRI for Local Staging of Colon Cancer: Can MRI Become the Optimal Staging Modality for Patients With Colon Cancer?

Nerad E, Lambregts DM, Kersten EL, Maas M, Bakers FC, van den Bosch HC, Grabsch HI, Beets-Tan RG, Lahaye MJ.

Dis Colon Rectum. 2017 Apr;60(4):385-392. doi: 10.1097/DCR.0000000000000794.

PMID:
28267005
8.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.

Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE.

Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.

9.

Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis.

Silva ANS, Coffa J, Menon V, Hewitt LC, Das K, Miyagi Y, Bottomley D, Slaney H, Aoyama T, Mueller W, Arai T, Tan IB, Deng N, Chan XB, Tan P, Tsuburaya A, Sakamaki K, Hayden JD, Yoshikawa T, Zondervan I, Savola S, Grabsch HI.

Ann Surg. 2018 Jan;267(1):114-121. doi: 10.1097/SLA.0000000000002042.

PMID:
27779515
10.

Erratum to: Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future.

van der Post RS, Gullo I, Oliveira C, Tang LH, Grabsch HI, O'Donovan M, Fitzgerald RC, van Krieken H, Carneiro F.

Adv Exp Med Biol. 2016;908:E1. No abstract available.

PMID:
27778307
11.

Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.

Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, West NP, Wright AI, Treanor D, Hewitt LC, Allum WH, Cunningham D, Hayden JD, Grabsch HI.

Oncotarget. 2016 Nov 22;7(47):77565-77575. doi: 10.18632/oncotarget.12723.

12.

Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future.

van der Post RS, Gullo I, Oliveira C, Tang LH, Grabsch HI, O'Donovan M, Fitzgerald RC, van Krieken H, Carneiro F.

Adv Exp Med Biol. 2016;908:371-91. doi: 10.1007/978-3-319-41388-4_18. Review. Erratum in: Adv Exp Med Biol. 2016;908:E1.

PMID:
27573781
13.

Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.

Hendrikx T, Watzenböck ML, Walenbergh SM, Amir S, Gruber S, Kozma MO, Grabsch HI, Koek GH, Pierik MJ, Staufer K, Trauner M, Kalhan SC, Jonkers D, Hofker MH, Binder CJ, Shiri-Sverdlov R.

BMC Med. 2016 Jul 22;14(1):107. doi: 10.1186/s12916-016-0652-0.

14.

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.

15.

Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.

Obulkasim A, Ylstra B, van Essen HF, Benner C, Stenning S, Langley R, Allum W, Cunningham D, Inam I, Hewitt LC, West NP, Meijer GA, van de Wiel MA, Grabsch HI.

Oncotarget. 2016 Jul 12;7(28):44084-44095. doi: 10.18632/oncotarget.9857.

16.

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.

Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, Mckiddie F, Ahearn T, Fleming I, Leeds J, Phull P, Park K, Nanthakumaran S, Matula KM, Grabsch HI, Tan P, Welch A, Schweiger L, Dahle-Smith A, Urquhart G, Finegan M, Petty RD.

Br J Cancer. 2016 Jun 14;114(12):e18. doi: 10.1038/bjc.2016.139. Epub 2016 May 26. No abstract available.

17.

Cervical esophageal cancer: a gap in cancer knowledge.

Hoeben A, Polak J, Van De Voorde L, Hoebers F, Grabsch HI, de Vos-Geelen J.

Ann Oncol. 2016 Sep;27(9):1664-74. doi: 10.1093/annonc/mdw183. Epub 2016 Apr 26. Review.

PMID:
27117535
18.

Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.

Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M.

Eur J Cancer. 2016 May;59:160-170. doi: 10.1016/j.ejca.2016.02.020. Epub 2016 Mar 31. Review.

PMID:
27039171
19.

Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A.

Rohwer N, Bindel F, Grimm C, Lin SJ, Wappler J, Klinger B, Blüthgen N, Du Bois I, Schmeck B, Lehrach H, de Graauw M, Goncalves E, Saez-Rodriguez J, Tan P, Grabsch HI, Prigione A, Kempa S, Cramer T.

Oncotarget. 2016 Feb 9;7(6):6693-710. doi: 10.18632/oncotarget.6793.

20.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S.

Br J Cancer. 2015 Dec 22;113(12):1747. doi: 10.1038/bjc.2015.458. No abstract available.

Supplemental Content

Loading ...
Support Center